Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A new study finds that inherited genetic variation plays a role in who is likely to benefit from cancer immunotherapies.
First-line Lenvima plus Keytruda yields better overall survival for patients with metastatic kidney cancer.
Experimental monoclonal antibody sotigalimab shows promising results in a Phase I study.
Researchers report that a personalized cancer vaccine called NeoVax may work to keep melanoma at bay
Altering gut bacteria may help overcome resistance to checkpoint inhibitors in people with melanoma and other cancers.
Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.
The coronavirus vaccines are safe and should be effective even for people with advanced cancer.
The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
The Damon Runyon Cancer Research Foundation awards $2.8 million to innovative early career scientists.
Scientists at Dana-Farber Cancer Institute have created molecular ON-OFF switches to regulate the activity of CAR T cells.
The National Cancer Institute discusses the progress of the Cancer Moonshot to accelerate cancer research.
Damon Runyon Cancer Research Foundation shares some exciting discoveries made by Damon Runyon researchers in 2020.
Study finds that using steroids to treat brain tumor symptoms may limit the effectiveness of immunotherapy drugs against these tumors.
Study offers assurance that the benefits of the combination can be achieved without diminishing patients’ quality of life.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.